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As many breast cancer cases are detected outside mammographic screening, a multidisciplinary quality management (QuaMaDi)
project involving gynaecologists, double reading by radiologists. and centralised assessment, documentation, evaluation and feedback
was implemented into routine breast cancer diagnosis in part of Schleswig-Holstein (Germany) with a population of 365000 women.
A cohort of 59514 patients eligible for diagnostic mammography was examined from May 2001 to December 2005 and quality
indicators, breast cancer incidence and tumour stage distribution were analysed. A total of 102744 diagnostic processes were initiated,
for 23.8% of which (24470) a third expert reading at the reference centre was performed. Further assessment was recommended for
6.3% (6442) of all patients. In total, 1056 breast cancer cases were diagnosed (10.3 per 1000 examinations). Patients of the QuaMaDi
project had a higher proportion of ‘in situ’ and T1 tumours (62.6% vs Schleswig-Holstein: 48.6%), showing that the implementation of
high standards in routine diagnostic mammography can improve the quality of breast cancer diagnosis and care.
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Although systematic screening programmes using mammography
to detect breast cancer have been implemented and evaluated
in different regions worldwide decades ago (Nystrom et al, 2002;
Tabar et al, 2003), the implementation of mammography
screening in Germany first began with three pilot regions in
2001 (Junkermann et al, 2001), and nationwide extension should
be reached by 2007. But even when a systematic screening
programme is established, it has to be kept in mind that it is aimed
only at asymptomatic women generally aged between 50 and 69
years. Women outside this age range or with breast cancer-related
symptoms are not eligible for screening programmes. These
women have to undergo breast cancer diagnosis in standard
care. Obviously, the diagnostic process of a screening programme
according to guidelines such as the European guidelines for
mammography screening (EUREF, 2006) is of an explicitly
higher quality than standard breast cancer diagnosis, especially
when different personnel are performing screening and diag-
nostic mammography (which will apply mainly for Germany). This
means that patients undergoing standard breast cancer diagnosis
may receive significantly lower quality diagnosis than asympto-
matic women in the screening situation. The epidemiology of
breast cancer shows that the problem of quality in standard
breast cancer diagnosis is real and relevant. Looking at the age
distribution of breast cancer, it is evident that 55% of all breast
cancer cases will occur outside the screening age group (when set
from 50 to 69 years) (Parkin et al, 2005). Taking participation rates
and interval cancer rates for the screening age group into account
approximately 75% of all breast cancer cases will be diagnosed in
the situation of standard care.
In Schleswig-Holstein, the northernmost federal state of
Germany, a process-orientated and comprehensive quality
management project was implemented to improve the standard
of breast cancer diagnosis (QuaMaDi¼Quality assured Mammo-
graphic Diagnosis). In this article, we examine whether quality
management in diagnostic breast imaging, following national and
international guidelines (EUREF, 2001, 2006; Albert and Schulz,
2004) can improve the quality of breast cancer diagnosis and care.
MATERIALS AND METHODS
Quality-assured mammary diagnostics
The process starts with the patient’s visit to the gynaecologist. This
is the usual pathway for patients with breast complaints in
Germany. The decision for mammography is based on a variety of
factors, including clinical findings (benign or suspicious), history
of breast cancer, family history of breast cancer, hormonal
replacement therapy. If mammography is indicated, the patient
is asked to participate in the project (with written informed
consent). The resulting mammogram is categorised using the
BI-RADS classification: 1¼negative, 2¼benign finding, 3¼probably
benign finding, 4¼suspicious abnormality, 5¼highly suspicious
of malignancy (ACR, 2003). Abnormal findings are defined as
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yBI-RADS 4 and 5. In cases of dense breast tissue (according to ACR
grade III or IV), an additional ultrasound examination is
performed. The mammogram and the ultrasound images are then
sent to a second radiologist, who carries out an independent
second reading (without knowledge of the result of the first
radiologist). In cases of BI-RADS 4 or 5 or of dissent findings
(BI-RADS 1/2 vs 3 vs 4/5), the documents are sent to a highly
specialised breast reference centre. If further assessment is
necessary, the patient is requested to visit the centre where,
depending on the individual case, noninvasive or invasive
examinations are performed.
Pilot region and study population
The pilot region is located in Schleswig-Holstein (SH, 2.8 million
inhabitants), the northernmost federal state of Germany. Approxi-
mately 365000 women (293000 older than 20 years) live in this
region. Women who were members of statutory health insurance
schemes (B80% of all women) were eligible to take part in
the project. Nearly all gynaecologists and radiologists in the
pilot region (84 gynaecologists, 20 radiologists) and one reference
centre took part in the project. Patients who were recommended a
biopsy (either percutaneous or open), which was not performed in
the reference centre, were followed up by the evaluation centre to
assess the final diagnosis and, in case of breast cancer, the tumour
stage. Cancer data (incidence and tumour stages) were compared
between the pilot region and the rest of the state on a popula-
tion basis using data from the regional cancer registry. For the
analysis of tumour stages, cases treated with neoadjuvant therapy
were excluded. Incidence rates were calculated as crude and
age-standardised rates in 100000 persons using World (WASR)
standard population.
Statistics
For descriptive statistics, we used absolute and relative frequencies
for qualitative data and mean values with standard deviations
(s.d.) and medians for quantitative data.
RESULTS
From May 2001 to December 2005, the participating gynaecologists
initiated 102744 diagnostic processes among 59514 patients
(Table 1). Of all patients, 76% stated that they had undergone
at least one mammography before inclusion in the project.
Actual clinical findings were found at the time of the visit to the
gynaecologist in 14.4% of all patients. Further demographic data
are described in Table 1.
Radiology
A total of 102744 mammography examinations were performed.
For 57.8%, an additional ultrasound was performed. The first
reader interpreted 4384 (4.3%) mammography examinations as
abnormal (BI-RADS 4:3625, 5:759).
For 97.6% (100358) of all mammograms a second independent
reading was carried out by another radiologist. For 811 cases
expert reading was carried out directly in the reference centre,
for 1516 cases second reading was not documented (for
unknown reasons).
In the group of patients with BI-RADS o5 at first view (Table 2),
the second reader classified 3205 additional cases (3.2% of
all examinations) as abnormal. In total, 7.4% of mammograms
were classified as abnormal after the second reading. Another
16463 (16.4%) patients showed dissent findings, with BI-RADS 3
interpretation by one radiologist and BI-RADS 1 or 2 by the
other (Table 2). Overall concordance of first and second reading
was 77.9%. The median time lag between first and second reading
was 3 days (mean 6.9714.7). Results with BI-RADS 5 in the
first reading were sent immediately to the reference centre (median
time 1 day).
Reference centre
For 23.8% (24470) of all radiological examinations, a third
reading at the reference centre was necessary because of BI-RADS
4 or 5 findings or dissent judgement between the first and
second radiologist (Table 3). As a result, further assessment was
recommended for 6442 cases (7.8% of these cases were judged as
BI-RADS 5, 85.0% as BI-RADS 4). Referring to all examinations,
the assessment rate was 6.3%.
In the reference centre, 5766 assessments were performed
(89.6% of all recommended assessments). Six hundred and
Table 1 Basic demographic data
Diagnostic processes
a N¼102744
Year
2001 7968 7.8%
2002 20559 20.0%
2003 23894 23.3%
2004 24023 23.4%
2005 26300 25.6%
Age
Mean and s.d. 54.9 (11.0)
Median and range 54 (18–95)
o50 years 36282 35.3%
50–69 years 57057 55.5%
4¼70 years 9405 9.2%
Body mass index 25.7 (4.9)
Nulliparous 19.4%
History of breast cancer 6.3%
Family history of breast cancer 15.5%
Age at menarche (in years) 13.6 (1.6)
Menopause 50.2%
Age at menopause (in years) 48.6 (6.3)
HRT
b (41year)
Of all patients 38.6%
Of menopausal patients 49.9%
Actual clinical findings
c 14792 14.4%
a59514 patients.
bHRT¼Hormonal replacement therapy.
cAny actual sign of
mastodynia, induration, nipple discharge, lump, lymph node enlargement or any
benign, unclear and malignant finding.
Table 2 Radiological examination – results of second reading after a
result of BI-RADS o5 at first reading: grey fields represent additional cases
for expert reading in the reference centre
Result of second reading (BI-RADS)
1 2 3 4 5 Total
Result of first reading (BI-RADS)
1 8896 6094 844 221 1 16056
2 10715 46932 7908 1708 4 67267
3 932 6779 4631 1265 6 13613
4 131 1040 1135 1086 30 3422
Total 20674 60845 14518 4280 41 100358
Dark grey fields: additional abnormal findings (BI-RADS 4/5). Light grey fields:
additional dissent findings BI-RADS 1/2 and 3.
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reference centre carried out 1540 bioptic procedures (26.7% of
all assessments in the centre, 15.0 per 1000 examinations),
which revealed 661 histologically verified breast cancer cases
(42.9%). In the group of 121 primarily recommended surgical
diagnoses, 84 (69.4%) breast cancer cases were identified; 73 cases
(25.5%) were identified within the group of recommended surgical
diagnosis after assessment. Within the group that had assess-
ment elsewhere 238 breast cancer cases were identified. In total,
1056 breast cancer cases were diagnosed by the project (10.3 per
1000 examinations).
Breast cancer incidence according to cancer registry data
In SH, 11525 breast cancer cases (including 588 in situ cases)
occurred between 1999 and 2003, 3201 (28%) of them in the pilot
region. Age-standardised breast cancer incidence (WASR) in the
pilot region increased by 7.5% after the start of the project in 2001
(1999–2000: 91.7/100000; 2001–2003: 98.5/100000). In the rest of
the state, the incidence was stable for invasive breast cancer
(1999–2000: 85.1/100000; 2001–2003: 86.3/100000) and for the in
situ incidence (4.5/100000). In the pilot region, a 100% increase of
the in situ incidence was seen (1999–2000: 5.2/100000; 2001–2003:
10.6/100000).
Tumour stage distribution
Hospital discharge letters or similar information were obtained
for 1006 primary breast cancer cases. Data for the T-category of
the TNM stage were compared to the epidemiological popula-
tion-based cancer registry data. Patients of the QuaMaDi project
had a higher proportion of ‘in situ’ and T1 tumours than that of
the whole country (62.6 vs 48.6%). Comparing the pilot region to
SH without QuaMaDi on the basis of cancer registry data, a
favourable tumour stage distribution could be found for the
QuaMaDi region (pilot region: 55.0% vs SH without QuaMaDi:
46.0%, Figure 1).
DISCUSSION
For a long time intensive efforts have been made to improve
the quality of mammography. These efforts have dealt mainly
with quality assurance in the field of mammography screening.
As a result of a high compliance to technical standards, usage
of diagnostic guidelines, and extensive documentation and
evaluation, very high-quality mammography within the screening
programmes can now be assumed (Klabunde et al, 2001, 2002).
The positive effects of mammography screening, like reduced
breast cancer mortality, have been evaluated in different pro-
grammes (Hackshaw, 2003).
In the field of diagnostic mammography quality is mainly
unknown, especially if mammograms are performed in a
decentralised system where a large number of radiologists are
involved with different technical and educational standards. There
is only a small amount of information on quality in diagnostic
mammography, such as from the Breast Cancer Surveillance
Consortium (BCSC) (Sickles et al, 2005) or from Denmark (Jensen
et al, 2006). The requirements for diagnostic mammography are
clearly lower than for screening mammography, at least in
Germany. The training conditions of radiologists in the field
of mammography are rather heterogeneous. There is no double
reading and the standards for further diagnostics vary. A serious
disadvantage is the nonexistent and/or nonstandardised docu-
mentation, which makes evaluation and audits impossible. The
QuaMaDi project has taken this unsatisfactory situation into
consideration and implemented multidisciplinary quality manage-
ment of the existing patterns of care.
Double reading of mammograms led to a 40% increase in the
most relevant group of abnormal findings (4.3% after first reading
to 7.4% after second reading). This increase is higher than that
reported for double reading in screening mammography. Ciatto
et al (2005) reports a 14% increase of referral from 3.15 to 3.59%
after double reading.
After the third reading, recommendation for further assessment
was given for only 6.3% of the primary mammography examina-
tions. This assessment rate is remarkably low for a diagnostic
Table 3 Reference centre: expert reading, assessment and tumour findings
Expert reading 24470 (23.8% of all examinations)
Time between second and expert reading (days)
a 14.7 (10.4) 13.0
Result
No breast cancer (radiological) 17827 72.9%
Assessment in reference centre recommended 6442 26.3% (6.3% of all examinations)
Open surgical biopsy recommended 121 0.5%
Other
b 80 0.3%
Assessments performed in the reference centre 5766 (89.6% of recommended assessments)
Time between expert reading and assessment (days)
a 30.8 (26.3) 26.0
Percutaneous interventions performed 1540 (26.7% of performed assessments)
Histologically verified breast cancer 661 42.9%
Benign findings 879 57.1%
Final assessment result
No breast cancer (clinical and radiological) 4714 81.8%
Histologically verified breast cancer 661 11.5%
Open surgical biopsy recommended 286 5.0%
Other
c 105 1.8%
Tumour findings
Total findings 1056 (10.3 per 1000 examinations)
aMean, standard deviation and median.
b20 missing cases, 57 cases where mammography had to be repeated, 1 case with no further diagnosis (metastases), 2 cases lost to follow
up.
c31 missing cases, 74 cases with need of further non operative diagnosis but lost to follow up.
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a cohort of women with self or general practitioner (GP) referral
(which might best be comparable to our cohort) (NHS Cancer
Screening Programmes, 2005). In Finland 4.6 and 2.3% of the
screened women were recalled at first and subsequent screens
(Sarkeala et al, 2004). In the Netherlands, the referral rate is only
1.38% at first screen (0.74% in subsequent screens) (Verbeek and
Broeders, 2003), but here the carcinoma interval rate is very high
(52%) (Fracheboud et al, 1999).
The biopsy rate (performed or primarily recommended) was
16.2 per 1000 examinations. It has to be emphasised that more
than 90% of the recommended biopsies were percutaneous
interventions. This means surgical biopsies were avoided as far
as possible. As expected, the rate of biopsies in the diagnostic
situation was higher than in a screening programme (Netherlands
initially: 9.7/1000, subsequently: 4.7/1000; Verbeek and Broeders,
2003). Breast cancer was histologically verified in 42.9% of all
biopsies performed in the reference centre. This percentage is
somewhat higher than that reported for the BCSC diagnostic
cohort (39.5% after biopsy) (Sickles et al, 2005) and only slightly
lower than in the Finnish screening programme (48.7%) (Sarkeala
et al, 2004).
In the QuaMaDi cohort, 10.3 cancer cases per 1000 examina-
tions were found. This corresponds with the results of the self
or GP referral group of the NHS screening with a breast cancer
rate of 8.3/1000 women (NHS Cancer Screening Programmes,
2005). Sickles et al (2005) report cancer detection rates between 8
and 50 cancer cases per 1000 examinations in different diagnostic
cohorts. In the screening situation, the cancer detection rates
are lower, because of the lower prevalence of breast cancer in an
asymptomatic population (6.5 cases/1000 in the Netherlands
(Verbeek and Broeders, 2003), 4.4 and 3.6 per 1000 women
(Sarkeala et al, 2004)).
Even though the diagnostic (process) quality in the QuaMaDi
project is close to screening for many indicators, we have to
question whether this also leads to a better outcome. As a
surrogate parameter, tumour stage distribution could be analysed,
assuming that favourable tumour stages would lead to longer
survival and less morbidity. The proportion of tumours with a
more favourable prognosis was 62.6% in the QuaMaDi cohort
(carcinoma in situ was 12.3%, T1 (o¼2cm) 50.3%). These results
are comparable to the diagnostic cohort described by Sickles et al,
(2005) (20% of carcinoma in situ) and the self-referral/GP group
of the NHS screening (17% of carcinoma in situ) (NHS Cancer
Screening Programmes, 2005). Fracheboud et al (2001) report
14% carcinoma in situ and 64% of T1 tumours in the group of
subsequently screened women.
Although QuaMaDi is not a screening programme, obvious and
remarkable effects on the population-based breast cancer in-
cidence and tumour stage distribution could be seen. After the
introduction of QuaMaDi, breast cancer incidence rose by 10% in
the pilot region, whereas it remained unchanged in other regions.
Breast cancer incidence in the pilot region (98.5/100000 WASR)
was higher than expected for Germany (79.8), western Europe
(84.6) and northern Europe (82.5) (Ferlay et al, 2004). A
comparable increase in breast cancer incidence has also been seen
in areas with screening programmes. In Norway, an increase of
13% in the female population was found comparing regions with
and without screening (Zahl et al, 2004). The improvement of
tumour stage distribution was not only found in the QuaMaDi
cohort itself, but also in the whole population. This effect was seen
both in the pre and post comparison of tumour stage in the pilot
region (data not shown) and in the comparison within SH.
At first sight, these population-based effects of QuaMaDi are
surprising, but in fact, only about 40% of all observed breast cancer
cases in the QuaMaDi region (cancer registry) were recorded in
the QuaMaDi project, for reasons that include the following: only
80% of the target population were members of the statutory health
insurance companies, thus making them eligible for the study;
informed consent was essential for participation; patients with
large tumours were often sent immediately to a hospital rather
than to diagnostic mammography. However, the improvement in
the personal skills of the gynaecologists and radiologists and the
technical improvement of the mammography equipment acquired
as a result of the QuaMaDi project benefit all patients of the region
regardless of their participation in the pilot project.
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Figure 1 Tumour stage distribution for the QuaMaDi cohort (2001–2004), SH in total and divided into region with and without QuaMaDi (2001–
2003).
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diagnostic mammography, including double reading of mammo-
grams, expert reading and centralised assessment, can lead to an
improved quality of structure, process and outcome in breast
cancer diagnosis, even in a decentralised setting. Unnecessary
biopsies, especially surgical biopsies, can be avoided and tumour
stage distribution can be improved, which should lead to a better
prognosis after breast cancer diagnosis. Even if QuaMaDi cannot
be directly and fairly compared to mammography screening, its
effects on breast cancer incidence and tumour stage distribution
are similar, showing that high-quality standards in diagnostic
mammography can improve breast cancer care complementary to
mammography screening. As at least two-thirds of all breast
cancer cases are diagnosed within standard care, detailed quality
management including documentation, evaluation and feedback
should be implemented for women outside the screening popula-
tion. This recommendation is in accordance with the new
European guidelines for quality assurance in mammography
screening and diagnosis (EUREF, 2006): ‘Ethically these principles
should be regarded as applying equally to symptomatic diagnostic
services and screening’.
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